(Q38765414)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

title

Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

author name string

M Hijaz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

J Chhina

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

I Mert

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

M Taylor

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Z Al-Wahab

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

R Ali-Fehmi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

T Buekers

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

A R Munkarah

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

R Rattan

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

language of work or name

English

0 references

publication date

16 June 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

volume

142

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

page(s)

323-331

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

Made-to-measure medicine: BRCA and gynaecological cancer

13 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Metformin: from mechanisms of action to therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Dietary energy balance modulates ovarian cancer progression and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

The antimitotic potential of PARP inhibitors, an unexplored therapeutic alternative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Metformin Induced AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal Squamous Cell Carcinomas In Vitro and In Vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Olaparib: a promising PARP inhibitor in ovarian cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Genome protective effect of metformin as revealed by reduced level of constitutive DNA damage signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Metformin reduces endogenous reactive oxygen species and associated DNA damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Enhanced cytotoxic effect of low doses of metformin combined with ionizing radiation on hepatoma cells via ATP deprivation and inhibition of DNA repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

AMP-activated protein kinase is a positive regulator of poly(ADP-ribose) polymerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

AMPK--sensing energy while talking to other signaling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.06.005

10.1016/J.YGYNO.2016.06.005

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27282964%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference